Primer: TransThera Sciences (Nanjing) (2617 HK) - Aug 2026
TransThera is a clinical-stage biopharmaceutical company with a pipeline focused on high-unmet-need areas, led by its core asset, Tinengotinib,...
96 Views
APAC Healthcare Weekly (Sept 20) –Sino Bio, Impact Therapeutics, Takeda, Daiichi Sankyo, SK Biopharm
NMPA accepted Sino Bio’s NDA for bispecific ADC drug candidate. FDA granted priority review to Takeda’s zasocitinib for moderate-to-severe plaque...
92 Views
TransThera Placement (2617 HK): Tinengotinib Alone Can’t Signal Any Major Upheaval of Fortunes
​TransThera announced placement of 5.1M shares at HK$57.03/share, with majority of proceeds to fund clinical trials for Tinengotinib. Potential...
178 Views
APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion
Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....
100 Views
TransThera (2617 HK) Placement: Fundraise Was Imminent, Tinengotinib Approval Near Term Trigger
​TransThera Sciences announces placement at HK$92.85/share, with focus on clinical trial of Tinengotinib. Tinengotinib will unleash its potential...
230 Views